In a practical overview of multisystem toxic effects of BRAF inhibitor/MEK inhibitor therapy, Welsh and Corrie10 provide suggestions for the management of BRAF inhibitor– and MEK inhibitor–associated hypertension. The gene discussed is BRAF; the disease is hypertensive disorder.